Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)

NCT07235033 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Uncomplicated Plasmodium Falciparum Malaria

Interventions

DRUG: KAE609
DRUG: SoC (Coartem)
DRUG: KLU156

Sponsor

Novartis Pharmaceuticals